JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bacopoulos, N. G.
Right arrow Articles by Roth, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bacopoulos, N. G.
Right arrow Articles by Roth, R. H.

Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey)

NG Bacopoulos, DE Redmond, J Baulu and RH Roth

Chronic treatment with haloperidol for 3 to 5 weeks (0.5 mg/kg, daily) resulted in significant increases of homovanillic acid (HVA) content in dorsal and orbital frontal cortex and in cingulate cortex. No change in HVA was seen in the olfactory cortex, basal ganglia, cisternal cerebrospinal fluid or plasma of animals chronically treated with haloperidol. Treatment with a single weekly dose of fluphenazine decanoate (5 mg/kg) for 3 weeks resulted in increased HVA levels in all the above brain regions, cisternal cerebrospinal fluid and plasma. Moreover, the fluphenazine-treated group had a significantly higher incidence of extrapyramidal side effects than the haloperidol-treated group. It is concluded that chronically increased dopamine metabolite production in the basal ganglia but not in cortex is reflected by increases in the HVA level of cerebrospinal fluid and plasma and is accompanied by severe extrapyramidal side effects.

Volume 212, Issue 1, pp. 1-5, 01/01/1980
Copyright © 1980 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
M. B. Knable and D. R. Weinberger
Dopamine, the prefrontal cortex and schizophrenia
J Psychopharmacol, January 1, 1997; 11(2): 123 - 131.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
S. D. Iversen
Is it possible to model psychotic states in animals?
J Psychopharmacol, January 1, 1987; 1(3): 154 - 176.
[PDF]

Home page
 ScienceHome page
D Pickar, R Labarca, M Linnoila, A Roy, D Hommer, D Everett, and S. Paul
Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
Science, August 31, 1984; 225(4665): 954 - 957.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics.